{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T01:00:56Z","timestamp":1780794056771,"version":"3.54.1"},"reference-count":45,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000130","name":"National Center for Chronic Disease Prevention and Health Promotion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti\u2010amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late\u2010onset Alzheimer's disease. This overlooks adults with Down syndrome (DS), who often experience dementia at a younger age and with different diagnostic assessment outcomes. This exclusion may deny DS adults access to potential disease\u2010modifying treatments. To address this issue, an international expert panel convened to establish adaptations of prescribing criteria suitable for DS patients and parameters for access to Centers for Medicare &amp; Medicaid Services (CMS) registries. The panel proposed mitigating disparities by modifying CMS and payer criteria to account for younger onset age, using alternative language and assessment instruments validated for cognitive decline in the DS population. The panel also recommended enhancing prescribing clinicians' diagnostic capabilities for DS and initiated awareness\u2010raising activities within healthcare organizations. These efforts facilitated discussions with federal officials, aimed at achieving equity in access to anti\u2010amyloid immunotherapeutics, with implications for national authorities worldwide evaluating these and other new disease\u2010modifying therapeutics for Alzheimer's disease.<\/jats:p>","DOI":"10.1002\/alz.13778","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:40:40Z","timestamp":1710376840000},"page":"3649-3656","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adapting prescribing criteria for amyloid\u2010targeted antibodies for adults with Down syndrome"],"prefix":"10.1002","volume":"20","author":[{"given":"Hampus","family":"Hillerstrom","sequence":"first","affiliation":[{"name":"LuMind IDSC Foundation Burlington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Fisher","sequence":"additional","affiliation":[{"name":"LuMind IDSC Foundation Burlington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-1748","authenticated-orcid":false,"given":"Matthew P.","family":"Janicki","sequence":"additional","affiliation":[{"name":"Department of Disability and Human Development University of Illinois Chicago Chicago Illinois USA"},{"name":"National Task Group on Intellectual Disabilities and Dementia Practices Rockport Maine USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chicoine","sequence":"additional","affiliation":[{"name":"Advocate Health, Advocate Medical Group Adult Down Syndrome Center Advocate Lutheran General Hospital Family Medicine Residency Park Ridge Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T.","family":"Christian","sequence":"additional","affiliation":[{"name":"Waisman Center IDDRC University of Wisconsin Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Esbensen","sequence":"additional","affiliation":[{"name":"Division of Developmental and Behavioral Pediatrics Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati Children's Hospital Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Esralew","sequence":"additional","affiliation":[{"name":"California Department of Developmental Services Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Sant Pau Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Department of Neurology Hospital de la Santa Creu i Sant Pau Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigan","family":"Hartley","sequence":"additional","affiliation":[{"name":"Waisman Center IDDRC University of Wisconsin Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hassenstab","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Psychological &amp; Brain Sciences Knight Alzheimer Disease Research Center Washington University St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Keller","sequence":"additional","affiliation":[{"name":"National Task Group on Intellectual Disabilities and Dementia Practices Rockport Maine USA"},{"name":"Neurology Associates of South Jersey Lumberton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Krinsky\u2010McHale","sequence":"additional","affiliation":[{"name":"Department of Psychology New York State Institute for Basic Research in Developmental Disabilities Island New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lai","sequence":"additional","affiliation":[{"name":"MGH Neurology Research Mass General Brigham Hospital Massachusetts General Hospital Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Neurology &amp; German Center of Neurodegenerative Diseases (DZNE) e.V. Ludwig\u2010Maximilians University Munich Germany"},{"name":"Department of Neurology Sahgrenska University Hospital M\u00f6lndal Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McCarron","sequence":"additional","affiliation":[{"name":"Trinity Centre for Ageing and Intellectual Disability Trinity College, University of Dublin Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McDade","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Psychological &amp; Brain Sciences Knight Alzheimer Disease Research Center Washington University St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Rebillat","sequence":"additional","affiliation":[{"name":"Outpatient Department Institut Jerome Lejeune Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminia Diana","family":"Rosas","sequence":"additional","affiliation":[{"name":"MGH Neurology Research Mass General Brigham Hospital Massachusetts General Hospital Boston Massachusetts USA"},{"name":"Department of Radiology Athinoula Martinos Center Massachusetts General Hospital Harvard Medical School Charlestown Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of California Irvine Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Strydom","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry Psychology and Neuroscience, Kings College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid H.","family":"Zaman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Cambridge Intellectual and Developmental Disabilities Research Group Cambridge University Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Institute for Stroke and Dementia Research Sahlgrenska Academy at the University of Gothenburg Molndal Sweden"},{"name":"Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Molndal Sweden"},{"name":"Munich Cluster for Systems Neurology (SyNergy) Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00245\u20103"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12910"},{"key":"e_1_2_6_4_1","unstructured":"deGraafG BuckleyF SkotkoB People living with Down syndrome in the USA: Births and population.2022. Accessed September 9 2023.https:\/\/go.dselink.net\/us\u2010population\u2010factsheet"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12390"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.8.3586"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1996.0003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205012666151020114607"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25573"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586\u2010023\u201000393\u20107"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001220"},{"key":"e_1_2_6_15_1","volume-title":"Adapting Eligibility Criteria for Prescribing FDA Approved Anti\u2010Amyloid Immunotherapeutics for Adults with Down Syndrome with Early\u2010Stage Alzheimer's Dementia","author":"Hillerstrom H","year":"2023"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-18096-0_116"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.17294\/2330\u20100698.1824"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163639"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4596"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.17131"},{"key":"e_1_2_6_21_1","unstructured":"Department of Veterans Affairs. VA formulary advisor.2023. Accessed August 20 2023.https:\/\/www.va.gov\/formularyadvisor\/"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12222"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_6_24_1","unstructured":"Alzheimer's Association.NIA\u2010AA revised diagnostic criteria: A biological definition of Alzheimer's disease (NIA\u2010AA Revised Clinical Criteria for Alzheimer's Disease).NIA and Alzheimer's association;2023. Accessed September 15 2023.https:\/\/aaic.alz.org\/diagnostic\u2010criteria.asp"},{"key":"e_1_2_6_25_1","unstructured":"Alzheimer's Association.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association 2 Workgroup. Draft Body Text as of October 9 2023.NIA and Alzheimer's association; January 3 2024.https:\/\/alz.org\/media\/Documents\/scientific\u2010conferences\/Clinical\u2010Criteria\u2010for\u2010Staging\u2010and\u2010Diagnosis\u2010for\u2010Public\u2010Comment\u2010Draft\u20102.pdf?_gl=1*exh9z4*_ga*MjA5MDIzNzc5My4xNzAwMjQyMDgy*_ga_QSFTKCEH7C*MTcwMTEyMjk5MC40LjEuMTcwMTEyMzIyOS42MC4wLjA.*_ga_9JTEWVX24V*MTcwMTEyMjk5MC40LjEuMTcwMTEyMzIyOS42MC4wLjA"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.22924"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13244"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.04.024"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17024"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13051"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12065"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010020\u201000740\u20106"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14443"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_6_35_1","unstructured":"ArmstrongA.Alzheimer's meds are here. But for the Down syndrome community It's still the 1980s.Fierce Biotech; March 1 2023. Accessed January 15 2024.https:\/\/www.fiercebiotech.com\/biotech\/down\u2010syndrome\u2010and\u2010alzheimers\u2010pharma\u2010clinical\u2010trials\u2010safety\u2010lecanemab"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.03.007"},{"key":"e_1_2_6_37_1","unstructured":"CMS.Statement: Broader Medicare coverage of Leqembi available following FDA traditional approval.CMS. July 06 2023. Accessed July 23 2023.https:\/\/www.cms.gov\/newsroom\/press\u2010releases\/statement\u2010broader\u2010medicare\u2010coverage\u2010leqembi\u2010available\u2010following\u2010fda\u2010traditional\u2010approval"},{"key":"e_1_2_6_38_1","unstructured":"SteenhuysenJ.Down syndrome families\u2019 fight for access to Alzheimer's trials treatments.Reuters. October 10 2023. Accessed October 15 2023.https:\/\/www.reuters.com\/business\/healthcare\u2010pharmaceuticals\/down\u2010syndrome\u2010families\u2010fight\u2010access\u2010alzheimers\u2010trials\u2010treatments\u20102023\u201010\u201010\/"},{"key":"e_1_2_6_39_1","unstructured":"DHHS\/ASPE.National Plan to Address Alzheimer's Disease.2023. Accessed September 30 2023.https:\/\/aspe.hhs.gov\/collaborations\u2010committees\u2010advisory\u2010groups\/napa\/napa\u2010documents\/napa\u2010national\u2010plan"},{"key":"e_1_2_6_40_1","unstructured":"National Task Group Workgroup on Neuroatypical Assessments.The changing landscape of care for adults with Down syndrome associated Alzheimer's disease (DS\u2010AD): Preparing for improvements in diagnostic assessments biomarkers and medical therapeutics Presented at: An \u2018in conjunction with event \u2019 American Academy of Neurology Boston Massachusetts; 25 April 2023; Boston MA. Accessed October 5 2023.https:\/\/www.the\u2010ntg.org\/key\u2010past\u2010events"},{"key":"e_1_2_6_41_1","volume-title":"After US Approval, Japan oks its First Alzheimer's Drug. Leqembi was Developed by Eisai and Biogen","author":"Yamaguchi M","year":"2023"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010023\u201000492\u20107"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.230595"},{"key":"e_1_2_6_44_1","unstructured":"BioArtic.European medicines agency accepts marketing authorization application for Lecanemab as treatment for early Alzheimer's disease.PR Newswire. Assessed on January 2 2024.https:\/\/www.prnewswire.com\/news\u2010releases\/european\u2010medicines\u2010agency\u2010accepts\u2010marketing\u2010authorization\u2010application\u2010for\u2010lecanemab\u2010as\u2010treatment\u2010for\u2010early\u2010alzheimers\u2010disease\u2010bioarctic\u2010301732125.html"},{"key":"e_1_2_6_45_1","unstructured":"Alzheimer Europe.Alzheimer Europe adopts position on anti\u2010amyloid therapies for Alzheimer's disease issuing a call to action for timely safe and equitable access.Alzheimer Europe.2024. Accessed January 9 2024.https:\/\/www.alzheimer\u2010europe.org\/policy\/positions\/alzheimer\u2010europe\u2010position\u2010anti\u2010amyloid\u2010therapies"},{"key":"e_1_2_6_46_1","unstructured":"McKieR.New Alzheimer's drugs bring hope of slowing disease for UK patients.The Guardian. December 17 2023. Accessed January 2 2024.https:\/\/www.theguardian.com\/society\/2023\/dec\/17\/new\u2010alzheimers\u2010drugs\u2010bring\u2010hope\u2010of\u2010slowing\u2010disease\u2010for\u2010uk\u2010patients"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.13778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:13:58Z","timestamp":1759936438000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.13778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/alz.13778"],"URL":"https:\/\/doi.org\/10.1002\/alz.13778","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}